What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx reported third-quarter net sales of $62 million, down 45% year over year, as wound care market disruption outweighed 9% growth in surgical revenue to $40 million. Wound care revenue fell 71% to $22 million following Medicare reimbursement changes that took effect at the beginning of 2026.

Analysis

The key issue is whether reimbursement pressure is resetting the economics of wound care or merely disrupting purchasing and billing during an adjustment period. If providers cannot make product use work under the new payment structure, reduced utilization could persist and weaken the value of MiMedx’s wound-care franchise beyond the initial revenue shock. That would also make the growing surgical business a less effective offset if it cannot scale quickly enough to replace lost contribution; revenue growth alone does not establish margin or cash-flow replacement.

Over the next 1–3 months, watch wound-care sales trends, management’s outlook, and any evidence that provider ordering is stabilizing. Over 6–18 months, the structural question is whether reimbursement rules or provider economics change enough to restore adoption. The contrarian case is that investors may extrapolate a severe decline indefinitely; a trough could emerge if utilization stabilizes, but the article provides no evidence yet. Without valuation, price reaction, profitability, or cash-flow data, the decline alone does not establish that MDXG is cheap or that an outright short is attractive.

Key Decisions for Investors

• Keep MDXG underweight/avoid adding until wound-care revenue shows stabilization; treat the next report and guidance as near-term catalysts rather than assuming a rapid recovery.
• For a tactical bearish position, consider shorting MDXG only if the stock fails to stabilize while wound-care sales or guidance continue to deteriorate. Define risk around a clear rebound or evidence of restored provider ordering; avoid an unhedged position based solely on the reported revenue decline.
• Before sizing a trade, verify gross margin and operating cash flow by business line, management’s updated outlook, and whether the reimbursement change is reducing utilization or chiefly delaying orders and billing. These determine whether surgical growth can offset wound-care losses economically.
• Falsify the bearish thesis if wound-care sales stabilize over subsequent quarters and cash generation holds up; strengthen it if guidance is cut again or provider demand continues to contract despite the initial reimbursement transition.